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WHAT THIS PAPER ADDS
 We present the design and rationale of the recently initiated SUPER study, a multicentre randomised controlled trial on supervised
exercise therapy or immediate PTA for intermittent claudication in patients with an iliac artery obstruction. Intermittent claudi-
cation is a common and disabling condition and there still is no consensus regarding the most optimal treatment for this large and
heterogeneous patient population. With this study we hope to inﬂuence future clinical practice and eventually provide a clinical
and cost-effective package of care for intermittent claudication in patients with an iliac artery obstruction.a r t i c l e i n f o
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Introduction: Treatment of intermittent claudication (IC) due to peripheral arterial disease (PAD) is aimed
at improving walking distance and includes secondary prevention of cardiovascular disease. Both
supervised exercise therapy (SET) and percutaneous transluminal angioplasty (PTA) have proven to be
effective in increasing maximum and pain-free walking distance in IC. However, the optimal treatment
strategy in patients with IC due to iliac artery stenosis or occlusion remains unclear.
Objective: To compare the (cost-) effectiveness of initial PTA versus initial SET in patients with disabling IC
due to an iliac artery obstruction.
Design: In a multicentre randomised controlled trial 400 consecutive patients with IC will be randomly
assigned to PTA (with additional stent placement on indication) or SET. Primary outcomes are maximum
walking distance and health-related quality of life measured using the disease-speciﬁc VascuQol
instrument after 1 year. Secondary outcomes are pain-free walking distance, functional status, generic
quality of life, complications related to each of the interventions, additional interventions, treatment
failures and costs (cost-effectiveness and cost-utility) after 1 year.
Conclusion and implications: Based on the results of this proposed large study well-founded adjustments
of existing guidelines on the treatment of iliac artery occlusive disease can be implemented (Clinical
Trials.gov NCT01385774; Nederlands Trial Register NTR2776).
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Treatment of patients with intermittent claudication (IC) is
aimed at increasing pain-free walking distance and subsequently
quality of life (Qol). Treatment also includes secondary prevention
of cardiovascular events by controlling risk factors for atheroscle-
rosis. Exercise programmes, percutaneous transluminal: þ31 20 5669432.
Koelemay).
bers listed in Appendix).
ciety for Vascular Surgery. Publishangioplasty (PTA), drugs and surgery can effectively relieve IC.1e4
Currently, the most frequently applied therapies for IC are exer-
cise programmes and PTA.4,5
A systematic review of eight randomised controlled trials (RCTs)
comparing both supervised and unsupervised exercise therapies
((S)ET) with PTA was unable to demonstrate the superiority of one
particular therapy with regard to walking distance and Qol. This
review included 702 patients with IC due to both aortoiliac and
femoropopliteal artery disease.6 The implications for patiented by Elsevier Ltd. All rights reserved.
F.A. Frans et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 466e471 467management based on this systematic review are unclear, as most
studies do not specify the degree of arterial obstruction. PTA of an
iliac artery obstruction is an attractive and effective treatment with
4-year patency rates of 70%.4 SET can also effectively improve pain-
free walking distance,7,8 but speciﬁcally in patients with iliac artery
stenosis or occlusion the beneﬁt of SET is unclear. The only pub-
lished high-quality RCT included 106 patients with an iliac artery
obstruction and could not demonstrate a difference in effectiveness
between PTA and SET, possibly because the study was underpow-
ered.9,10 Thus, the optimal treatment strategy of patients with IC
due to an iliac artery obstruction still needs to be deﬁned.
The objective of the SUPER study is to compare the clinical
effectiveness and the cost-effectiveness of SET and PTA as treat-
ment for IC due to an iliac artery obstruction. We hypothesise that
ﬁrst-line treatment with PTA is more effective than SET with regard
to maximum walking distance (MWD), Qol and costs after 1 year.
Methods
Setting
SUPER study is a multicentre randomised controlled trial and
will be conducted in 15 Dutch hospitals and their allied local
physiotherapy practices. The study aims to include 400 consecutive
outpatients with IC who are able to walk a distance of between 100
and 300m on a treadmill at 3.2 km h1 and 10% incline. All patients
must have an iliac artery obstruction with a diameter reduction
50% as assessed by colour duplex scanning (CDS), magnetic
resonance angiography (MRA) or computed tomography angiog-
raphy (CTA). Usually, patients are referred by a general practitioner
to the participating hospital where they are further evaluated by
a vascular surgeon. A concomitant>50% stenosis or occlusion in theFigure 1. Eligibisuperﬁcial femoral artery (SFA) is not a contraindication to inclu-
sion. For all inclusion and exclusion criteria, see Fig. 1. The ﬁnal
results of the trial will be reported in line with the CONSORT
(CONsolidated Standards of Reporting Trials) statement.11
Ethics and informed consent
The study will be conducted according to the principles of the
Declaration of Helsinki (World Medical Association Declaration of
Helsinki Ethical Principles for Medical Research Involving Human
Subjects Version Edinburgh, Scotland, October 2000), with Note of
Clariﬁcation on Paragraph 29 added by the WMA General
Assembly, Washington 2002 end Note of Clariﬁcation on Paragraph
30 added by the WMA General Assembly, Seoul 2008 and in
accordance with the Medical Research Involving Human Subjects
Act (WMO) and other guidelines, regulations and Acts.12 Patients
can only participate in the study when they fulﬁl the inclusion
criteria and give written informed consent. The study has been
approved by the Medical Ethical Committee at the Academic
Medical Center, Amsterdam (MEC 09/285). The SUPER study is
registered under Trial registration NTR2776 and NCT01385774.13,14
Treatment groups
Participating patients will be randomly allocated to SET or PTA.
SET group
SET will be either hospital-based or community-based in
accordance with the guidelines of the Royal Dutch Society for
Physiotherapists.15 SET will be given for 6 months. It will start with
a frequency of 2 times a week for 12 weeks, then once a week for 8lity criteria.
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patients are regarded sufﬁciently trained and will perform the
training on their own. Compliance to SET is recorded by the phys-
iotherapist (PT) at 1, 3 and 6 months. Furthermore, we will ask the
patients at the 12 months’ follow-up visit if they have had SET by
a PT between 6 and 12 months.
A well-designed SUPER study SET programme has been created.
The summary of this programme is shown in Fig. 2. The SET pro-
gramme is sent in advance to each PT practice, whowill train a SUPER
study patient. We will refer each SUPER study patient only to a dedi-
cated trained PT,who is able to offer SETaccording to the SUPER study
SET programme. In addition, we will perform visits and interviews
with the PT practices to check if the programme is indeed executed.
PTA group
The PTA procedure will be performed by an experienced inter-
ventional radiologist. An experienced radiologist is ofﬁcially
registered with and certiﬁed by the Dutch society of Interventional
Radiology. An additional stent will be placed if the residual mean
pressure gradient is greater than 10mmHg across the treated site or
in case of a residual stenosis of more than 30%, which is considered
a poor initial result.16,17 All PTA patients will be encouraged to
undertake at least three walking sessions every day.
Cardiovascular risk factor management and background therapy
In accordance with the Dutch guideline “Diagnosis and treat-
ment of peripheral arterial disease of the lower extremity,”18 irre-
spective of cholesterol levels, all patients will receive a statin, anti-
platelet therapy (aspirin 100 mg) and, if necessary, blood pressure-
lowering therapy (targets 140/90 mmHg and 130/80 mmHg in
diabetics). Patients will be advised to stop smoking.
Co-intervention
If, after a minimum of 6 months, IC continues to be persistent
and disabling in patients allocated to SET, a delayed PTA may be
carried out. Also, if persistent disabling IC continues after initial
PTA, the patient may be referred for additional SET. Persistent
disabling IC is deﬁned as persisting symptoms perceived by the
patient. Delayed PTA or additional SET will be considered as
treatment failure.
Randomisation
Randomisation will be computer- and web-based using strati-
ﬁcation to ensure a balanced distribution of known possibleFigure 2. Description of Superviconfounders in both treatment groups, and in blocks of variable
size. Randomisation will be stratiﬁed according to the following
characteristics: MWD at baseline (less or more than 200 m), and
concomitant SFA stenosis or occlusion. To ensure allocation
concealment the randomisation list has been generated using an
online computer software program (ALEA NKI-AVL, Amsterdam,
The Netherlands, Release: 2.2.) and implemented into the web-
based application.
Assessments
Fig. 3 shows the timeline of patient inclusion and follow-upwith
accompanying assessments. Follow-up assessments are scheduled
at 1, 6 and 12 months after start of treatment, SET or PTA.
e At baseline and follow-up visits pain-free and MWD will be
assessed using a treadmill test which, in accordance with the
Trans Atlantic Inter-Society Consensus (TASC) guidelines, is set
at 3.2 km h1 and 10% incline.3 At follow-up visits (at 1, 6 and
12 months) the treadmill test will be recorded by an observer
who is blinded to treatment allocation. For logistical reasons
the MWD will be set at 800 m, equivalent to 15 min on the
treadmill, at the three follow-up assessments.
e The ankleebrachial index (ABI), deﬁned as the ratio of the
highest systolic pressure of the dorsal pedal and posterior tibial
arteries divided by the highest of both brachial systolic pres-
sures,19 will be measured at rest and after the treadmill test.
e CDS, MRA or CTA will be used to grade patency of the iliac
artery in patients allocated to the PTA group after 12 months.
e Health-relatedQol and functional outcomequestionnaireswillbe
used to measure patient-centred outcomes such as ambulatory
status, activities of daily life (ADL), independence and perceived
psychosocialwell-being.20,21 Forhealth-relatedQoL, bothgeneric
Qol, using EQ-5Dand Short Form36 (SF-36)22 questionnaires and
disease-speciﬁc Qol, using the Vascular Quality of Life (VascuQol)
questionnaire, will be used.23e25 Generic scales are less sensitive
in detecting subtle changes in Qol.
e Functional outcome will be evaluated by the AMC Linear
Disability Score (ALDS). The ALDS is a generic item bank used to
assess the level of ADL in patients with chronic disease.26 The
ALDS item bank contains 77 items covering awide scale of daily
activities. From the item bank, clinicians can select the items
that are most applicable to the population that they are
investigating (‘best’ items). Based on clinical relevance and
adapted to the disability level of this speciﬁc patient group, 28
items have been selected for the current study. The scores
range from 0 to 100 and lower scores correspond with a higher
level of disability. Previous evaluation of ALDS in patients insed Exercise Therapy (SET).
Figure 3. Timeline SUPER study.
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internal reliability, consistency and correlationwith the activity
domain of the VascuQol.27,28 All four questionnaires (EQ-5D,
SF-36, VascuQol and ALDS) will be recorded at baseline,1, 6 and
12 months’ follow-up. The EQ-5D will also be completed at 1-
week follow-up.
Outcomes
Primary outcomes are MWD on a standardised treadmill test at
a speed of 3.2 km h1 at 10% incline, and Qol measured using the
disease-speciﬁc VascuQol instrument after 1 year.
Secondary outcomes are pain-free walking distance on the
treadmill, functional status as assessed by the AMC Linear Disability
Score (ALDS), generic Qol measured with the SF-36 and EQ-5D,
complications related to both interventions, treatment failures
(deﬁned as crossover to the other treatment arm), additional
interventions and costs after 1 year (Fig. 4).
Analysis
Analysis is carried out according to the intention-to-treat prin-
ciple. Baseline characteristics are summarised using descriptive
statistics. Differences in MWD and Qol at 12 months between the
treatment groups will be compared with a two-tailed unpaired t-
test, and, if necessary, multiple linear regression to take into
account unbalanced baseline values of the VascuQol and treadmill
test. Additionally, the repeated data structure of both primary
outcomes is analysed using a mixed linear model.
For comparisons of the secondary outcomes, depending on the
distribution of data the c2-test or Fisher’s exact test, unpaired t-test
or ManneWhitney test are used. In all analyses, statistical uncer-
tainties are expressed in 95% conﬁdence intervals and p-values
<0.05 will indicate statistical signiﬁcance.Figure 4. Primary and secondary outcomes after one year.Sample size
Since little is known about the expected treatment effect that
will be revealed on the continuous VascuQol scale, Cohen’s effect
size d is used as the benchmark to assess the relative magnitude of
score differences between each of the treatment groups. We
assume a moderate effect (d ¼ 0.4) on Qol and MWD. A sample size
of 180 patients in each group has 90% power to detect a difference
in VascuQol score means of 0.377 between the SET and the PTA
group, at a two-sided signiﬁcance level of 5% (assuming overall
VascuQol scores of 4600 and 4977 (common standard deviation
(SD) 1.1), respectively).
Using an unpaired t-test with a 0.05 two-sided signiﬁcance
level, this sample size also has 90% power to detect a difference in
means of 86 mMWD on a treadmill at a speed of 3.2 km h1 at 10%
incline (SET group mean of 250 m and the PTA group mean of
336 m) assuming a common SD of 250 m. Anticipating a maximum
dropout rate of 10%, 200 patients need to be included in each
treatment arm.
Cost-effectiveness analysis
The economic evaluation of PTA versus SET will be performed
from a societal perspective as a cost-effectiveness analysis with the
costs per patient able to walk 250 m at a speed of 3.2 km h1 with
a 10% incline as a primary outcome measure.
Additionally, a cost-utility analysis will be carried out with the
costs per quality adjusted life-year (QALY) as outcome. The EQ-5D is
used to generate health status scoring proﬁles over time, which will
subsequently be translated into QALYs by applying time trade-off-
based health-utility algorithms and assuming that interpolation
between successive measurements best reﬂects a patient’s health
status during the year.29,30
The time horizon for the cost-effectiveness as well as cost-utility
analysis is 1 year.
The evaluation will include the direct medical costs, out-of-
pocket expenses and the indirect non-medical costs of produc-
tivity losses. Volume data will be gathered with clinical report
forms, available hospital information systems and the Dutch Health
and Labour Questionnaire adapted for this patient population (to be
completed at baseline, and at months 1, 6 and 12). Unit costing will
comply with the Dutch costing manual for health-care research.
After price-indexing all costs will be expressed in euros for the base
year 2011.
The sample size of 400 patients (accounting for 10% dropout) is
sufﬁcient to detect clinically relevant differences in QALYs based on
the EQ-5D, which is a generic health status measure that is less
sensitive than the disease-speciﬁc VascuQol. Starting at a baseline
health utility level of about 0.69 (SD 0.2) in the study population,10
we expect a 10% improvement in the SET arm, resulting in a health
utility of 0.759 following treatment. A clinically relevant difference
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ment (i.e., by 20%). Given the follow-up duration of 12 months, the
sample size of 180 patients per group has 90% power to detect
a difference in means of 0.069 in QALYs (SET group mean of 0.759
QALY and the PTA group mean of 0.828 QALY) assuming a common
SD of 0.2 QALY and using a 0.05 two-sided signiﬁcance level.
Safety monitoring
To ensure the safety of each study subject a Data Safety Moni-
toring Committee (DSMC) has been established. The DSMC will not
only advise the SUPER study investigators regarding the continuing
safety of study participants but also ensure the integrity of the
study conduct and results, provide an independent review of safety
and will review the formal safety analysis. Two interim analyses of
safety are planned for this study.
Safety analysis
There is no formal safety stopping guideline for this study, since
both treatments are standard clinical care. The DSMC may recom-
mend stopping the study at any time for signiﬁcant safety issues.
The DSMCmay also recommend an unplanned interim analysis due
to safety concerns.
Other considerations
In our systematic review, we found no evidence for the supe-
riority of any combination of SET and PTA over another. Yet, it is
common practice to refer a patient with IC and an iliac obstruction
for a PTA and not SET. The aim of our study is therefore to compare
the relative effectiveness of both treatments. It would be relevant to
compare other combinations, such as SET versus SET and PTA, or
PTA versus SET and PTA, as such studies will determine the addi-
tional value of the combination of interventions over a single
intervention. We know that a third study arm with a combination
strategy with PTA and SET would provide more answers, but due to
logistic reasons, costs and the fact that a much larger sample size
would be needed to detect clinically relevant differences we
decided to restrict the study to a head-to-head comparison of PTA
and SET.
Conclusion and Implications
As multiple vascular specialists are involved in the care of
patients with intermittent claudication, knowledge transfer is
primarily aimed at these health-care professionals. The results of
this study will contribute to existing guidelines on the treatment of
iliac artery occlusive disease. Implementation of the results and
guidelines will be facilitated by the broad network of participating
hospitals (a wide spectrum of institutions including academic and
teaching hospitals), and allied physiotherapy practices.
This study will be the largest RCT on this subject to be carried
out so far and the impact of the ﬁndings will therefore be
substantial, from both a practical and a scientiﬁc point of view. The
ofﬁcial SUPER study inclusionwill start in September 2011. With an
inclusion period of 2 years and 1-year follow-up, the ﬁrst results are
expected by the end of 2014.
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